Clinical trial
Determination of Safe Dose of Romiplostim (AMG 531) in Patients With…
NCT00303472 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00303472 |
|---|---|
| Title | Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS) |
| Official title | An Open Label, Sequential Cohort, Dose Escalation Study to Evaluate the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thrombocytopenia, MDS, Myelodysplastic Syndromes, Refractory Cytopenias |
| Intervention type | Drug |
| Interventions | Romiplostim |
| Enrollment | 72 |
| Start date | Feb 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Mar 17, 2006 |
| Last update posted | Dec 16, 2013 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: